Specific to individual cancer types, LUAD and LUSC have relatively high Hub-EGFR.Sig scores among cancers, and ample evidence has confirmed that EGFR tyrosine kinase inhibitors indeed prolong the PFS of NSCLC patients (94, 95). This evidence concerns the gene EGFR and non-small cell lung carcinoma.